Longevity & Anti-aging

Ipamorelin / CJC-1295 Mix

64,99 €

SKU IPA-CJC-MIX
For in vitro research use only. Not for human or animal consumption.

Overview

This formulation combines two complementary growth hormone-axis peptides acting via distinct but synergistic receptor pathways: Ipamorelin (a selective ghrelin receptor agonist) and CJC-1295 (a GHRH analogue with Drug Affinity Complex technology for extended half-life).

Ipamorelin

  • Selective GH Release: Stimulates GH release without significantly affecting cortisol, ACTH, or prolactin – a cleaner research model for GH pulsatility studies than earlier-generation GHRPs.
  • GHS-R1a Agonism: Acts on the primary ghrelin receptor subtype for GH secretagogue activity.
  • Molecular Weight: 711.86 g/mol | CAS: 170851-70-4

CJC-1295

  • GHRH Analogue: Modified GHRH(1-29) with DAC technology enabling covalent albumin binding, extending bioactive half-life from minutes to days in animal models.
  • Pituitary Research: Studied for sustained stimulation of somatotroph cells and downstream GH/IGF-1 axis effects.
  • Molecular Weight: 3647.28 g/mol | CAS: 863288-34-0

Combination Rationale

Ipamorelin triggers a sharp GH pulse via the GHRP pathway; CJC-1295 amplifies and prolongs GH release via the GHRH pathway. Combined, they create a synergistic somatotroph stimulation studied in body composition, metabolic, and anti-ageing research models.

For in vitro laboratory research use only. Not for human or animal administration.